Clinical trials: HHT, active
Hereditary Hemorrhagic Telangiectasia
Body Donation in HHT
The possibility of body donation in hereditary hemorrhagic telangiectasia (HHT) means that human tissue samples with and without vascular malformations can be analyzed. The aim is to gain insights into the disease mechanism.
- Trial name
- NCT07826845
- Testing
- body donation in HHT
- Where
- Germany
- Volunteers
- 5 people
- Sponsor
- University Hospital, Essen
Haemorrhagic Hereditary Telangiectasia
Institutional Registry of Haemorrhagic Hereditary Telangiectasia
The purpose of this study is to create an institutional and population-based registry of Haemorrhagic Hereditary Telangiectasia with a prospective survey based on epidemiological data, risk factors, diagnosis, prognosis…
- Trial name
- NCT01761981
- Where
- Argentina
- Volunteers
- 590 people
- Sponsor
- Hospital Italiano de Buenos Aires
Hereditary Hemorrhagic Telangiectasia (HHT)
Phase 1b Study of TX002100 in Participants With Hematologic Support-Dependent Hereditary Hemorrhagic Telangiectasia (HHT)
The primary purpose of this study is to assess the safety and tolerability of TX002100 in participants with hereditary hemorrhagic telangiectasia (HHT).
- Trial name
- NCT07863609
- Testing
- TX002100
- Volunteers
- 20 people
- Sponsor
- Tectonic Operating Company, Inc.
Hereditary Hemorrhagic Telangiectasia
A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
The purpose of this study is to: evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-6400 in healthy volunteers evaluate the efficacy, safety, tolerability and PD of…
- Trial name
- InsigHHT (NCT06659640)
- Testing
- ALN-6400
- Where
- 16 sites in United States, Australia and 4 more
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Telangiectasia, Hereditary Hemorrhagic, Intracranial Arteriovenous Malformations
Hereditary Hemorrhagic Telangiectasia and Neurovascular Manifestations, in the Danish HHT Database
With a described prevalence of brain arteriovenous malformations (CAVM) of 12.8% in HHT patients, of whom 10% presents with intracranial hemorrhage, HHT pose a risk of devastating intracranial hemorrhage.
- Trial name
- DAN-HEMTEL-VM (NCT05933330)
- Testing
- Brain MRI
- Where
- Denmark
- Volunteers
- 300 people
- Sponsor
- Odense University Hospital
Newly Diagnosed Mixed Phenotype Acute Leukemia (MPAL)
HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL).
This study aims to evaluate the safety and efficacy of homoharringtonine combined with venetoclax and azacitidine regimen (HVA) in newly diagnosed MPAL patients, providing a basis for the use of the HVA regimen in the treatment…
- Trial name
- HVA-MPAL (NCT07517510)
- Testing
- HVA
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Guangdong Second Provincial General Hospital
Bevacizimab, HHT
Bevacizumab in the Treatment of HHT
Clinical Study Abstract (Ethics Application) Hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant vascular disorder characterized by recurrent intractable epistaxis and multi-organ arteriovenous malformations.
- Trial name
- NCT07828015
- Testing
- Bevacizumab, nasal electrocoagulation., Thalidomide (50mg)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hereditary Haemorrhagic Telangiectasia
Immunological Effects of Iron Supplementation in HHT Disease
Hereditary haemorrhagic telangiectasia (HHT), is a rare genetic vascular disorder with autosomal dominant inheritance. Its prevalence is estimated at approximately 1 in 6,000 individuals in France.
- Trial name
- Fer&RO (NCT07111598)
- Testing
- Blood test at D0, Blood test at D+3 months
- Where
- France
- Volunteers
- 155 people
- Sponsor
- Hospices Civils de Lyon
Newly Diagnosed Acute Myeloid Leukemia With High Risk
HVA vs IA/DA or VA in the Treatment of ND HR-AML
The aim of this study is to evaluate the safety and efficacy of homohartonine combined with venetoclax and azacitidine (HVA) versus intensive chemotherapy (IA/DA) or venetoclax combined with azacitidine (VA) in newly diagnosed…
- Trial name
- NCT06810791
- Testing
- HVA, VA, Standard Chemotherapy
- Where
- China
- Volunteers
- 876 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Prostate CA
Clinical Study on Neoadjuvant Therapy of Homoharringtonine Combined With Androgen Deprivation for Prostate Cancer
The high incidence of prostate cancer is one of the important diseases that threaten the health of old men in our country. Although androgen deprivation therapy is an important treatment option for prostate cancer, although…
- Trial name
- NCT06834321
- Testing
- Homoharringtonine combined with androgen deprivation therapy, radical prostatectomy
- Where
- 2 sites in China
- Volunteers
- 96 people
- Sponsor
- baotai Liang
Hereditary Hemorrhagic Telangiectasia, Rendu Osler Disease
Prospective Study of Antiplatelet and Anticoagulation Therapy in Hereditary Haemorrhagic Telangiectasia
The goal of this clinical trial is to evaluate in real life, in patients with Hereditary Hemorrhagic Telangiectasia (HHT), the tolerance of the strategy of use of anticoagulant and/or antiplatelet, by comparing a new exposure…
- Trial name
- PROPLACO-Tel (NCT05641142)
- Testing
- monitoring the use of anticoagulant and/or antiplatelet therapy in patients with osler rendering disease
- Where
- 18 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Clermont-Ferrand
Hereditary Hemorrhagic Telangiectasia, Pulmonary Arterial Hypertension
DIAG723 in Adults With Hereditary Hemorrhagic Telangiectasia
This is a Phase 1/2, randomized, double-blind, placebo-controlled, first-in-human study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of subcutaneously administered DIAG723 in adult patients with…
- Trial name
- DIAMOND (NCT07623525)
- Testing
- DIAG723
- Where
- 11 sites in Australia, Canada and 1 more
- Volunteers
- 93 people
- Sponsor
- Diagonal Therapeutics, Inc.
Telangiectasia, Hereditary Hemorrhagic
Case Notes Review on Patients With Hereditary Haemorrhagic Telangiectasia
This observational study is for individuals with Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations that are reviewed at the Hammersmith Hospital, London.
- Trial name
- NCT00230685
- Where
- United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Imperial College London
Hereditary Hemorrhagic Telangiectasia
Bevacizumab In Hereditary Hemorrhagic Telangiectasia
This research study is studying to see whether bevacizumab may treat chronic bleeding and iron deficiency anemia in Hereditary Hemorrhagic Telangiectasia (HHT).
- Trial name
- TrUST-HHT (NCT04404881)
- Testing
- Bevacizumab (Avastin®)
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Hanny Al-Samkari, MD
AML (Acute Myeloid Leukemia)
Chidamide, Venetoclax, Azacitidine, and Homoharringtonine for High-risk Fit AML
This study aims to explore a superior first-line induction remission regimen by incorporating Chidamide into the modified VAH chemotherapy combined with targeted therapy regimen, leveraging its dual epigenetic modulation…
- Trial name
- NCT07643636
- Testing
- Chidamide (Chi)+VAH
- Volunteers
- 46 people
- Sponsor
- Dongguan People's Hospital
Prostate Cancer
Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoadjuvant Treatment of High-Risk Prostate Cancer: A Multicenter Prospective, Single-Arm Clinical Study
Previous study findings suggest that the efficacy limitations of the neoadjuvant treatment regimen combining docetaxel with androgen deprivation therapy are associated with protein synthesis.
- Trial name
- NCT07516704
- Testing
- Docetaxel+ Darolutamide + Homoharringtonine+ Androgen Deprivation Therapy
- Volunteers
- 94 people
- Sponsor
- Zhongda Hospital
Hereditary Hemorrhagic Telangiectasia
Quality of Life in Patients With Hemorrhagic Telangiectasia
Hereditary Hemorrhagic Telangiectasia (HHT), also known as Osler's disease, is a genetic disorder that leads to abnormal blood vessel formations.
- Trial name
- NCT06261333
- Testing
- Questionnaires
- Where
- Germany
- Volunteers
- 250 people
- Sponsor
- University Hospital, Essen
Hereditary Haemorrhagic Telangiectasia
Evaluation of Video-assisted Instructions of Nasal Self-packing in Patients with HHT
Inserting nasal self-packings is a secure method leaving patients more self-confident. We provide a video on https://www.youtube.com/watch?v=LaioLYfSJ-E demonstrating how to use nasal self-packings.
- Trial name
- NCT03841422
- Testing
- video-assisted nasal self-packing
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- University Hospital, Essen
Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease
Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)
This is a 2-part study evaluating ATV-1601 in participants with moderate to severe HHT. Part 1 is a randomized, double-blind, placebo-controlled study evaluating 3 dosing regimens of ATV-1601.
- Trial name
- NCT07601425
- Testing
- ATV-1601
- Where
- 8 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Atavistik Bio, Inc
Acute Myeloid Leukemia (AML)
Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure
Venetoclax (Ven) resistance is common in the treatment of acute myeloid leukemia (AML). Patients with Ven resistance have poor response and survival, except those with specific targeted therapy.
- Trial name
- HLA-AML (NCT07813390)
- Testing
- Lisaftoclax (APG-2575), homoharringtonine, Azacitidine (AZA)
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Guangdong Second Provincial General Hospital